Extradural Motor Cortex Stimulation in Parkinson's Disease: Long-Term Clinical Outcome.

Enrico Di Stasio, Anna Rita Bentivoglio, Antonio Daniele, Paolo Calabresi, Carla Piano, Francesco Bove, Alfonso Fasano, Beatrice Cioni, Tommaso Tufo, D Mulas

Research output: Contribution to journalArticlepeer-review

Abstract

Previous investigations have reported on the motor benefits and safety of chronic extradural motor cortex stimulation (EMCS) for patients with Parkinson’s disease (PD), but studies addressing the long-term clinical outcome are still lacking. In this study, nine consecutive PD patients who underwent EMCS were prospectively recruited, with a mean follow-up time of 5.1 ± 2.5 years. As compared to the preoperatory baseline, the Unified Parkinson’s Disease Rating Scale (UPDRS)-III in the off-medication condition significantly decreased by 13.8% at 12 months, 16.1% at 18 months, 18.4% at 24 months, 21% at 36 months, 15.6% at 60 months, and 8.6% at 72 months. The UPDRS-IV decreased by 30.8% at 12 months, 22.1% at 24 months, 25% at 60 months, and 36.5% at 72 months. Dopaminergic therapy showed a progressive reduction, significant at 60 months (11.8%). Quality of life improved by 18.0% at 12 months, and 22.4% at 60 months. No surgical complication, cognitive or behavioral change occurred. The only adverse event reported was an infection of the implantable pulse generator pocket. Even in the long-term follow-up, EMCS was shown to be a safe and effective treatment option in PD patients, resulting in improvements in motor symptoms and quality of life, and reductions in motor complications and dopaminergic therapy.
Original languageEnglish
Pages (from-to)1-12
Number of pages12
JournalBrain Sciences
Volume2021
Publication statusPublished - 2021

Keywords

  • Parkinson's Disease

Fingerprint

Dive into the research topics of 'Extradural Motor Cortex Stimulation in Parkinson's Disease: Long-Term Clinical Outcome.'. Together they form a unique fingerprint.

Cite this